Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes a meta-analysis

JAMA - Journal of the American Medical Association

Volumn 316, Issue 3, 2016, Pages 313-324

  Palmer, Suetonia C ^a   Mavridis, Dimitris ^b   Nicolucci, Antonio ^c   Johnson, David W ^d   Tonelli, Marcello ^e   Craig, Jonathan C ^f   Maggo, Jasjot ^a   Gray, Vanessa ^a   De Berardis, Giorgia ^c   Ruospo, Marinella ^g,h   Natale, Patrizia ^a,h   Saglimbene, Valeria ^a,h   Badve, Sunil V ^d,i   Cho, Yeoungjee ^d   Nadeau Fredette, Annie Claire ^j   Burke, Michael ^d   Faruque, Labib ^k   Lloyd, Anita ^c   Ahmad, Nasreen ^c   Liu, Yuanchen ^c   Tiv, Sophanny ^c   Wiebe, Natasha ^l   Strippoli, Giovanni F M ^f,h,m   more..

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF IOANNINA   (Greece)

^c Center for Outcomes Research and Clinical Epidemiology (CORESEARCH)   (Italy)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF SYDNEY   (Australia)

^g UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^h Diaverum Medical Scientific Office   (Sweden)

ⁱ GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^j UNIVERSITÉ DE MONTRÉAL   (Canada)

^k ROYAL ALEXANDRA HOSPITAL   (Canada)

^l UNIVERSITY OF ALBERTA   (Canada)

^m University of Alberta ^*  (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; RISK; TREATMENT FAILURE;

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TREATMENT FAILURE;

EID: 84978976076     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.9400     Document Type: Article

References (34)

1. World Health Organization (WHO). Global Health Estimates 2014 Summary Tables. WHO website. http://www.who.int/healthinfo/global-burden-disease/en/. 2014. Accessed June 21, 2016.
2. Murray CJL, Vos T, Lozano R., et al. Disability-adjusted life-years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 [published correction appears in Lancet. 2013; 381(9867):628].
3. Lancet. 2012; 380(9859):2197-2223.
4. American Diabetes Association. Standards of medical care in diabetes - 2015, 7: approaches to glycemic treatment. Diabetes Care. 2015; 38(suppl): S41-S48.
5. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013; 36(4):1033-1046.
6. Holman RR, Sourij H, Califf RM Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014; 383 (9933):2008-2017.
7. Bennett WL, Maruthur NM, Singh S, et al Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011; 154(9):602-613.
8. Zinman B, Wanner C, Lachin J.M., et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22):2117-2128.
9. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes [published online June 13, 2016]. N Engl J Med. 2016. doi:10.1056/NEJMoa1603827.
10. Hutton B, Salanti G, Caldwell D.M., et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162(11):777-784.
11. Gross JL, Kramer CK, Leitão CB, et al; Diabetes and Endocrinology Meta-analysis Group (DEMA). Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med. 2011; 154(10):672-679.
12. Higgins JP, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-188.
14. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum; 1988.
15. Lu G, Ades AE Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004; 23(20):3105-3124.
16. Caldwell DM, Ades AE, Higgins JP Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005; 331(7521): 897-900.
17. Chaimani A, Higgins JP, Mavridis D, Spyridonos P., Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One. 2013; 8(10): e76654.
18. White IR. Network meta-analysis. Stata J. 2015; 15(4):951-985.
19. White IR, Barrett JK, Jackson D, Higgins JP Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012; 3(2): 111-125.
20. Spiegelhalter D, Abram K, Myles J. Bayesian Approaches to Clinical Trials and Health-care Evaluation. Hoboken, NJ: John Wiley & Sons; 2004.
21. Turner RM, Davey J, Clarke M.J., Thompson SG, Higgins JP. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. Int J Epidemiol. 2012; 41(3):818-827.
22. Rhodes KM, Turner RM, Higgins JPT. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol. 2015; 68(1):52-60.
23. Veroniki AA, Vasiliadis HS, Higgins J.P., Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013; 42(1):332-345.
24. Higgins JP, Jackson D, Barrett J.K., Lu G., Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2012; 3(2): 98-110.
25. Osman A, Otero J, Brizolara A., et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J. 2004; 147(5):e23.
26. Ovalle F, Bell DS Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care. 2004; 27(11):2585-2589.
27. Sohn TS, Lee JI, Kim I.J., Min KW, Son HS. The effect of rosiglitazone and metformin therapy, as an initial therapy, in patients with type 2 diabetes mellitus. Korean Diabetes J. 2008; 32(5):445-452.
28. Matthews DR, Dejager S, Ahren B., et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010; 12(9): 780-789.
29. Salanti G, Del Giovane C, Chaimani A, Caldwell D.M., Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS One. 2014; 9 (7):e99682.
30. Green JB, Bethel MA, Armstrong P.W., et al; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373(3):232-242.
31. Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14):1317-1326.
32. Singh S, Loke YK, Furberg CD Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007; 298(10):1189-1195.
33. Lincoff AM, Wolski K, Nicholls S.J., Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007; 298(10):1180-1188.
34. Simmons RK, Echouffo-Tcheugui JB, Sharp S.J., et al. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. Lancet. 2012; 380(9855):1741-1748.